Brief: Tg Therapeutics Announces Global License Agreement With Precision Biosciences

TG Therapeutics

09/01/2024 12:23

Jan 9 (Reuters) - Precision BioSciences Inc  DTIL.O :
    * TG THERAPEUTICS ANNOUNCES GLOBAL LICENSE AGREEMENT WITH
PRECISION BIOSCIENCES FOR THE DEVELOPMENT AND COMMERCIALIZATION
OF PRECISION’S ALLOGENEIC CD19 CAR T CELL THERAPY PROGRAM FOR
THE TREATMENT OF AUTOIMMUNE DISEASES
    * TG THERAPEUTICS INC - TG THERAPEUTICS WILL RECEIVE
EXCLUSIVE
WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE AZER-CEL IN
NON-ONCOLOGY INDICATIONS
    * TG THERAPEUTICS INC - PRECISION WILL RECEIVE UPFRONT AND
POTENTIAL NEAR-TERM ECONOMICS VALUED AT $17.5 MILLION
    * TG THERAPEUTICS INC - UPFRONT PAYMENT OF $7.5 MILLION WILL
CONSIST OF CASH AND PURCHASE OF PRECISION COMMON STOCK BY TG
THERAPEUTICS
    * TG THERAPEUTICS - PRECISION WILL RECEIVE $2.5 MILLION IN
DEFERRED CONSIDERATION DUE WITHIN 12 MONTHS AS AN EQUITY
INVESTMENT IN PRECISION'S COMMON STOCK
    * TG THERAPEUTICS INC - PRECISION ELIGIBLE TO RECEIVE UP TO
$288
MILLION IN ADDITIONAL PAYMENTS BASED ON ACHIEVEMENT OF CERTAIN
MILESTONES

Source text for Eikon:  ID:nGNXVbSgZ 
Further company coverage:  DTIL.O 

 ((Reuters.Briefs@thomsonreuters.com;))